CL2020002096A1 - Inhibidores de arginasa y sus métodos de uso. - Google Patents
Inhibidores de arginasa y sus métodos de uso.Info
- Publication number
- CL2020002096A1 CL2020002096A1 CL2020002096A CL2020002096A CL2020002096A1 CL 2020002096 A1 CL2020002096 A1 CL 2020002096A1 CL 2020002096 A CL2020002096 A CL 2020002096A CL 2020002096 A CL2020002096 A CL 2020002096A CL 2020002096 A1 CL2020002096 A1 CL 2020002096A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- compounds
- formula
- arginase inhibitors
- arginase
- Prior art date
Links
- 102000004452 Arginase Human genes 0.000 title abstract 2
- 108700024123 Arginases Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se divulgan compuestos de fórmula (Ia) o una sal farmacéuticamente aceptable de estos, composiciones farmacéuticas que comprenden compuestos de fórmula (Ia) y métodos para utilizarlas en el tratamiento del cáncer o una enfermedad respiratoria inflamatoria y la inhibición de la arginasa, donde R1 es -NHR1a; R1a es -H o -C(O)CH(R1b)NHR1c; y R1b se selecciona entre -H, -alquilo (C1-C4) y CH2OR1d y R1c es -H; o R1b y R1c, junto con el átomo al que están unidos, forman un anillo heterocíclico de 5 miembros; y R1d es H o –CH3.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862631659P | 2018-02-17 | 2018-02-17 | |
| US201862671576P | 2018-05-15 | 2018-05-15 | |
| US201862721113P | 2018-08-22 | 2018-08-22 | |
| US201862778002P | 2018-12-11 | 2018-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002096A1 true CL2020002096A1 (es) | 2020-12-18 |
Family
ID=65763693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002096A CL2020002096A1 (es) | 2018-02-17 | 2020-08-13 | Inhibidores de arginasa y sus métodos de uso. |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11420984B2 (es) |
| EP (1) | EP3752251A1 (es) |
| JP (2) | JP7317841B2 (es) |
| KR (1) | KR102657919B1 (es) |
| CN (3) | CN117186134A (es) |
| AU (2) | AU2019221896B2 (es) |
| BR (1) | BR112020015973A2 (es) |
| CA (1) | CA3091365A1 (es) |
| CL (1) | CL2020002096A1 (es) |
| CR (1) | CR20200418A (es) |
| DO (1) | DOP2020000145A (es) |
| EC (1) | ECSP20058183A (es) |
| IL (1) | IL276711B2 (es) |
| JO (1) | JOP20200197A1 (es) |
| MA (1) | MA51837A (es) |
| MX (1) | MX2020008570A (es) |
| NI (1) | NI202000055A (es) |
| PE (1) | PE20210176A1 (es) |
| SG (1) | SG11202007739XA (es) |
| TW (1) | TWI803574B (es) |
| UY (1) | UY38096A (es) |
| WO (1) | WO2019159120A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7317841B2 (ja) * | 2018-02-17 | 2023-07-31 | アストラゼネカ・アクチエボラーグ | アルギナーゼインヒビタ及びその使用方法 |
| PE20211001A1 (es) | 2018-02-27 | 2021-06-01 | Incyte Corp | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b |
| WO2019186497A1 (en) | 2018-03-29 | 2019-10-03 | Oncoarendi Therapeutics S.A. | Dipeptide piperidine derivatives |
| MX2020012376A (es) | 2018-05-18 | 2021-03-09 | Incyte Corp | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. |
| AU2019297361B2 (en) | 2018-07-05 | 2024-06-27 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
| CN112584900A (zh) * | 2018-08-22 | 2021-03-30 | 阿斯利康(瑞典)有限公司 | 精氨酸酶抑制剂及其使用方法 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| US20220409642A1 (en) * | 2019-11-04 | 2022-12-29 | Astrazeneca Ab | Combination therapy for treating cancer |
| TW202228720A (zh) * | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2560978B1 (en) | 2010-04-22 | 2019-01-30 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| EP3719024A1 (en) | 2010-10-26 | 2020-10-07 | Mars, Incorporated | Arginase inhibitors as therapeutics |
| RU2019121905A (ru) * | 2010-12-31 | 2019-09-03 | Астразенека Юкей Лимитед | Ингибиторы аргиназы и способы их применения |
| JP6152167B2 (ja) * | 2012-04-18 | 2017-06-21 | マーズ インコーポレイテッド | アルギナーゼ阻害剤としての環拘束性類似体 |
| UA123700C2 (uk) * | 2015-06-23 | 2021-05-19 | Калітера Байосайєнсиз, Інк. | Композиції і способи інгібування активності аргінази |
| KR20220118559A (ko) | 2015-10-30 | 2022-08-25 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 아르기닌 활성 억제용 조성물 및 방법 |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| MX2019005402A (es) | 2016-11-08 | 2019-12-05 | Calithera Biosciences Inc | Terapias de combinacion del inhibidor de arginasa. |
| SG10201911243WA (en) | 2016-12-22 | 2020-02-27 | Calithera Biosciences Inc | Compositions and methods for inhibiting arginase activity |
| WO2019120296A1 (en) | 2017-12-22 | 2019-06-27 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as arginase inhibitors |
| JP7317841B2 (ja) * | 2018-02-17 | 2023-07-31 | アストラゼネカ・アクチエボラーグ | アルギナーゼインヒビタ及びその使用方法 |
| WO2019177873A1 (en) | 2018-03-13 | 2019-09-19 | Merck Sharp & Dohme Corp. | Arginase inhibitors and methods of use |
| WO2019205979A1 (zh) | 2018-04-27 | 2019-10-31 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途 |
| WO2019218904A1 (zh) | 2018-05-18 | 2019-11-21 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、其制备方法及用途 |
| WO2019245890A1 (en) | 2018-06-20 | 2019-12-26 | Merck Sharp & Dohme Corp. | Arginase inhibitors and methods of use |
-
2019
- 2019-02-15 JP JP2020543307A patent/JP7317841B2/ja active Active
- 2019-02-15 EP EP19710796.4A patent/EP3752251A1/en active Pending
- 2019-02-15 AU AU2019221896A patent/AU2019221896B2/en active Active
- 2019-02-15 PE PE2020001241A patent/PE20210176A1/es unknown
- 2019-02-15 MX MX2020008570A patent/MX2020008570A/es unknown
- 2019-02-15 IL IL276711A patent/IL276711B2/en unknown
- 2019-02-15 CN CN202311155200.XA patent/CN117186134A/zh active Pending
- 2019-02-15 KR KR1020207026580A patent/KR102657919B1/ko active IP Right Grant
- 2019-02-15 CN CN201980013045.3A patent/CN111712302B/zh active Active
- 2019-02-15 US US16/969,739 patent/US11420984B2/en active Active
- 2019-02-15 JO JOP/2020/0197A patent/JOP20200197A1/ar unknown
- 2019-02-15 UY UY0001038096A patent/UY38096A/es unknown
- 2019-02-15 CR CR20200418A patent/CR20200418A/es unknown
- 2019-02-15 CN CN202311157009.9A patent/CN117180290A/zh active Pending
- 2019-02-15 MA MA051837A patent/MA51837A/fr unknown
- 2019-02-15 BR BR112020015973-5A patent/BR112020015973A2/pt unknown
- 2019-02-15 SG SG11202007739XA patent/SG11202007739XA/en unknown
- 2019-02-15 CA CA3091365A patent/CA3091365A1/en active Pending
- 2019-02-15 WO PCT/IB2019/051236 patent/WO2019159120A1/en active Application Filing
- 2019-02-15 TW TW108105043A patent/TWI803574B/zh active
-
2020
- 2020-07-22 DO DO2020000145A patent/DOP2020000145A/es unknown
- 2020-08-13 CL CL2020002096A patent/CL2020002096A1/es unknown
- 2020-08-14 NI NI202000055A patent/NI202000055A/es unknown
- 2020-09-16 EC ECSENADI202058183A patent/ECSP20058183A/es unknown
-
2022
- 2022-06-07 AU AU2022203938A patent/AU2022203938B2/en active Active
- 2022-07-15 US US17/812,736 patent/US20230122859A1/en active Pending
-
2023
- 2023-07-10 US US18/349,336 patent/US11912727B2/en active Active
- 2023-07-19 JP JP2023117406A patent/JP2023145557A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002096A1 (es) | Inhibidores de arginasa y sus métodos de uso. | |
| CO2021015698A2 (es) | Moduladores de thr-β y métodos de uso de estos | |
| PE20230238A1 (es) | Inhibidores de kras g12c | |
| PE20190329A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| CO6251294A2 (es) | Derivados de 9-(pirazol-3-il)-9h-purin-2-amina y 3-(pirazol-3-il)-3h-imidazol4,5-b piridin-5-amina y su uso para el tratamiento del cancer | |
| AR081725A1 (es) | Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer | |
| PE20190106A1 (es) | Inhibidores del potenciador del homologo zeste 2 | |
| AR087212A1 (es) | ANTAGONISTAS DE CRTh2 | |
| CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| ECSP22027784A (es) | Derivados de 2azaespiro[3.4]octano como agonistas de m4 | |
| CO2021011039A2 (es) | Inhibidores de arginasa y métodos de uso de estos | |
| PE20210404A1 (es) | Derivados de pirrolo [1,2-b] piridazina | |
| AR088775A1 (es) | Derivados heterociclicos diazeniodiolato de amina primaria | |
| EA202091886A1 (ru) | Ингибиторы аргиназы и способы их применения | |
| AR114394A1 (es) | Inhibidores de arginasa y sus métodos de uso | |
| EA202190009A1 (ru) | Производные бензимидазола и их применение в качестве ингибиторов idh1 | |
| AR101413A1 (es) | Inhibidores de la tirosina cinasa de bruton | |
| EA202090241A1 (ru) | Новые гетероциклические соединения как ингибиторы cdk8/19 | |
| AR115780A2 (es) | Azepinas y oxazepinas condensadas como inhibidores de la proteína quinasa 1, composición farmacéutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la proteína quinasa 1 | |
| AR114666A1 (es) | Derivados de isoindolin-1,3-diona, un intermediario para su síntesis, una composición farmacéutica que los comprende y el uso de los mismos en el tratamiento de enfermedades inflamatorias y de cáncer | |
| AR116966A1 (es) | Inhibidores de quinasa dependiente de ciclina 7 (cdk7) | |
| AR114263A1 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| AR104597A1 (es) | Compuestos tricíclicos como agentes antineoplásicos |